The Australian experience of government subsidisation of novel oral anticoagulants (NOACs) Online Only
NOACs offer physicians an alternative to warfarin for stroke prevention in atrial fibrillation (AF). The Pharmaceutical Benefits Scheme (PBS) is the system whereby the Australian Government subsidises medications for defined indications. Initially NOACs were only subsidised for specific venous thromboembolism treatment and prevention indications. Authorities to prescribe NOACs for prevention of stroke in at-risk patients with AF were added to the PBS in August 2013 for rivaroxaban, and September 2013 for apixaban and dabigatran.
A. Vlachadis Castles, W. van Gaal
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.
Resource Library Item
This resource is available for registered members of CSANZ.
Click the button below to log in to HeartOne and access this resource. Please note that CPD credit is NOT automatically assigned for accessing resources directly.